Target Glucose metabolism (FDG)Class Glucose analogueOther names FDG, 2-deoxy-2-fluoro-D-glucose
Structure from the cited PubChem record (unlabelled ligand, or the labelled form when PubChem only describes that one). Conformer: PubChem (3D conformer computed by PubChem). Rotate with the mouse or a finger.
| Form | Use | Molar mass (labelled form) | Ongoing trials | Most advanced phase | Approval |
|---|---|---|---|---|---|
| [¹⁸F]FDG Syntheses and QC ↗ | Imaging | 181.15 | 113 | Phase 3 | FDG (many manufacturers) US EU FR JP |
Atlas trials whose studied drug or title names this vector, with this radionuclide.
| Trial | Phase | Status | Sponsor | Countries |
|---|---|---|---|---|
| [18F]FDGNCT01394679 · Non-small-cell lung cancer | Phase 3 | Not yet recruiting | Cell>Point LLC | 1 |
| [18F]FDGNCT05015881 · Psychiatry and addiction | Phase 3 | By invitation | University of Pennsylvania | 1 |
| FAP ligands (FAPI)NCT07535554 · Bacterial infections | Phase 3 | Recruiting | Universitaire Ziekenhuizen KU Leuven | 1 |
| HISTIOGEN · [18F]FDGNCT04943211 · Other | Phase 3 | Active, not recruiting | Anna Raciborska | 1 |
| [18F]FDGNCT07245849 · Other | Phase 3 | Not yet recruiting | Ottawa Heart Institute Research Corporation | 0 |
| [18F]FDGNCT04143516 · Solid tumors (multiple indications) | Phase 3 | Recruiting | Memorial Sloan Kettering Cancer Center | 1 |
| [18F]FDG2025-522349-23-00 · Neuroinflammation and multiple sclerosis | Phase 3 | Recruiting | Amsterdam UMC Stichting | 1 |
| STB-XTR-003 · [18F]FDGNCT07443696 · Ischemic heart disease | Phase 2 | Recruiting | Sinotau Pharmaceutical Group | 1 |
| CRAFT · [18F]FDGNCT06335888 · Atherosclerosis and vessels | Phase 2 | Recruiting | Insel Gruppe AG, University Hospital Bern | 1 |
| [18F]FDGNCT05710328 · Breast | Phase 2 | Active, not recruiting | ECOG-ACRIN Cancer Research Group | 2 |
| [18F]FDG2023-509923-42-00 · Breast | Phase 2 | Recruiting | Medica Scientia Innovation Research S.L. | 5 |
| [18F]FDG2023-504145-31-00 · Breast | Phase 2 | Recruiting | Narodowy Instytut Onkologii Im. Marii Sklodowskiej-Curie-Panstwowy Instytut Badawczy | 1 |
| [18F]FDGNCT04275453 · Healthy volunteers (dosimetry, biodistribution) | Phase 2 | Recruiting | University of Pennsylvania | 1 |
| [18F]FDGNCT04316117 · Breast | Phase 2 | Active, not recruiting | ECOG-ACRIN Cancer Research Group | 3 |
| [18F]FDGNCT07471776 · Breast | Phase 2 | Recruiting | Fudan University | 1 |
| [18F]FDGNCT06956391 · Solid tumors (multiple indications) | Phase 2 | Recruiting | Akiva Mintz | 1 |
| [68Ga]Ga-DOTA-TATE/TOC/NOC2024-516156-18-00 · NETs and neuroendocrine carcinomas (other) | Phase 2 | Recruiting | Rigshospitalet | 1 |
| GRAIL · [18F]FDGNCT06050694 · Lymphoma | Phase 2 | Recruiting | University Health Network, Toronto | 1 |
| IMPACT · [18F]FDGNCT05308888 · Atherosclerosis and vessels | Phase 2 | Recruiting | University Hospital, Brest | 1 |
| [18F]FDG2023-510506-41-00 · Small-cell lung cancer | Phase 2 | Recruiting | TheraOp gGmbH | 1 |
| [18F]FDOPANCT05255159 · NETs and neuroendocrine carcinomas (other) | Phase 2 | Active, not recruiting | University of Alberta | 1 |
| [18F]FDGNCT07508852 · Small-cell lung cancer | Phase 2 | Recruiting | Peking University First Hospital | 1 |
| [18F]FDG2023-508478-27-00 · Lymphoma | Phase 2 | Recruiting | European Organisation For Research And Treatment Of Cancer | 7 |
| [18F]FDG2024-516131-28-00 · NETs and neuroendocrine carcinomas (other) | Phase 2 | Recruiting | Rigshospitalet | 1 |
| [18F]FDG2024-514353-30-00 · Inflammatory diseases | Phase 1 | Recruiting | Assistance Publique Hopitaux De Paris | 1 |
| [18F]FDGNCT02285192 · Gynecological | Phase 1 | Active, not recruiting | Memorial Sloan Kettering Cancer Center | 1 |
| [18F]FDGNCT06385652 · Myeloma | Phase 1 | Recruiting | Peking University First Hospital | 1 |
| Amyloid tracers2024-519961-23-00 · Alzheimer's disease and cognitive disorders | Phase 1 | Not yet recruiting | Barcelonabeta Brain Research Center | 1 |
| [18F]FDGNCT04219904 · Gynecological | Phase 1 | Active, not recruiting | M.D. Anderson Cancer Center | 1 |
| [18F]FDGNCT05892393 · Myeloma | Phase 1 | Recruiting | Robert Flavell, MD, PhD | 1 |
| [18F]FDGNCT07023861 · Breast | Phase 1 | By invitation | Affiliated Hospital of Jiangnan University | 1 |
| [18F]FDGNCT06717113 · Myeloma | Phase 1 | Recruiting | Peking University First Hospital | 1 |
| [18F]FDGNCT07838649 · Other | Phase 1 | Not yet recruiting | Washington University School of Medicine | 1 |
| [18F]FDGNCT07023848 · Breast | Phase 1 | By invitation | Affiliated Hospital of Jiangnan University | 1 |
| [18F]FDGNCT02390635 · Leukemia / transplant conditioning | Phase 1 | Recruiting | M.D. Anderson Cancer Center | 1 |
| FAP ligands (FAPI)NCT05121779 · Inflammatory diseases | Phase 1 | Recruiting | Peking Union Medical College Hospital | 1 |
| [18F]FDGNCT06014515 · Atherosclerosis and vessels | Phase 1 | Recruiting | University of California, Davis | 1 |
| [18F]FDGNCT07604207 · Atherosclerosis and vessels | Phase 1 | Not yet recruiting | Massachusetts General Hospital | 0 |
| [18F]FDGNCT05876858 · Other | Phase 1 | Active, not recruiting | University of California, Davis | 1 |
| GBM · [18F]fluciclovineNCT06613841 · Brain (glioma, medulloblastoma…) | Phase 1 | Recruiting | Abramson Cancer Center at Penn Medicine | 1 |
| [18F]FDGNCT06914999 · Atherosclerosis and vessels | Phase 1 | Recruiting | Emory University | 1 |
| [18F]FDGNCT02213497 · Stomach / esophagus | Phase 1 | Active, not recruiting | Abramson Cancer Center at Penn Medicine | 1 |
| [18F]FDGNCT04362644 · Inflammatory diseases | Phase 1 | Recruiting | University of Alabama at Birmingham | 1 |
| [18F]FDGNCT07301801 · Solid tumors (multiple indications) | Phase 1 | Recruiting | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 1 |
| [18F]FDGNCT06453915 · Neuroinflammation and multiple sclerosis | Phase 1 | Recruiting | University of California, Davis | 1 |
| MVTEP2/SOME2 · [18F]FDGNCT04304651 · Solid tumors (multiple indications) | No phase | Active, not recruiting | University Hospital, Brest | 2 |
| NVALT31-PET · [18F]FDGNCT06082492 · Small-cell lung cancer | No phase | Recruiting | Radboud University Medical Center | 1 |
| MONITOR-RCT · [18F]FDGNCT06877949 · Breast | No phase | Recruiting | Odense University Hospital | 3 |
| CARTEP · [18F]FDGNCT07029295 · Heart failure and cardiomyopathies | No phase | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 1 |
| PERPETUAL · [18F]FDGNCT07130344 · Breast | No phase | Not yet recruiting | Centre Paul Strauss | 1 |
| PREDICT · [18F]FDGNCT07454096 · Atherosclerosis and vessels | No phase | Not yet recruiting | Fundacion Clinic per a la Recerca Biomédica | 1 |
| CET-PET-PUO · [18F]FDGNCT07816783 · Other | No phase | Recruiting | Post Graduate Institute of Medical Education and Research, Chandigarh | 1 |
| FAP ligands (FAPI)NCT06421142 · Bladder / urothelial | No phase | Recruiting | First Affiliated Hospital of Fujian Medical University | 1 |
| SMART-PET · [18F]FDGNCT07884487 · Breast | No phase | Active, not recruiting | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | 1 |
| FAP ligands (FAPI)NCT04416165 · Solid tumors (multiple indications) | No phase | Recruiting | The First Affiliated Hospital of Xiamen University | 1 |
| [18F]FDGNCT04478318 · Melanoma | No phase | Active, not recruiting | University of California, Davis | 1 |
| [18F]FDGNCT06017973 · Epilepsy | No phase | Recruiting | Universitaire Ziekenhuizen KU Leuven | 1 |
| INCOGNITO · [18F]FDGNCT05733416 · Stroke and trauma | No phase | Recruiting | Ottawa Hospital Research Institute | 1 |
| PanTumPET · [18F]FDGNCT06842615 · Solid tumors (multiple indications) | No phase | Recruiting | Comenius University | 1 |
| [18F]FDGNCT06511323 · Other | No phase | Not yet recruiting | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | 0 |
| [18F]AlF-NOTA-PRGD2 (alfatide)NCT06416852 · Small-cell lung cancer | Phase 3 | Not yet recruiting | Yantai LNC Biotechnology Singapore PTE. LTD. | 1 |
| [68Ga]Ga-DOTA-TATE/TOC/NOC2024-519505-35-00 · Gastroenteropancreatic NETs | Phase 3 | Recruiting | Centre Hospitalier Universitaire De Nantes | 1 |
| [18F]DCFPyL (piflufolastat)NCT03173924 · Prostate – other | Phase 2 | Active, not recruiting | National Cancer Institute (NCI) | 1 |
| [68Ga]Ga-PSMA-11NCT03181867 · Prostate – localised / recurrence | Phase 2 | Active, not recruiting | National Cancer Institute (NCI) | 1 |
| FAP ligands (FAPI)NCT06503146 · Pheochromocytoma / paraganglioma | Phase 2 | Recruiting | National Cancer Institute (NCI) | 1 |
| FAP ligands (FAPI)2025-524874-41-00 · Sarcoma / bone | Phase 2 | Not yet recruiting | Rigshospitalet | 1 |
| PD-1/PD-L1 tracersNCT07848243 · Breast | Phase 2 | Recruiting | Peking University Cancer Hospital & Institute | 1 |
| FAP ligands (FAPI)NCT07285993 · Breast | Phase 2 | Not yet recruiting | Randy Yeh | 1 |
| Antagonistes GRPRNCT05549024 · Prostate – other | Phase 1 | Recruiting | Peking Union Medical College Hospital | 1 |
| FAP ligands (FAPI)NCT06740240 · Solid tumors (multiple indications) | Phase 1 | Recruiting | First Affiliated Hospital of Fujian Medical University | 1 |
| Integrin tracers (RGD)NCT06632860 · NETs and neuroendocrine carcinomas (other) | Phase 1 | Recruiting | Peking Union Medical College Hospital | 1 |
| [18F]BCPP-EF (complexe mitochondrial I)NCT07825818 · Psychiatry and addiction | Phase 1 | Recruiting | Rajesh Narendran | 1 |
| Amyloid tracersNCT00950430 · Alzheimer's disease and cognitive disorders | No phase | By invitation | Mayo Clinic | 1 |
| FAP ligands (FAPI)NCT06791226 · Solid tumors (multiple indications) | No phase | Recruiting | Peking University Third Hospital | 1 |
| FAP ligands (FAPI)NCT06653452 · Colorectal | No phase | Recruiting | Peking Union Medical College Hospital | 1 |
| BCMA tracerNCT07353554 · Myeloma | No phase | Not yet recruiting | Peking Union Medical College Hospital | 1 |
| [18F]PSMA-1007NCT06723665 · Prostate – other | No phase | By invitation | Affiliated Hospital of Jiangnan University | 1 |
| FAP ligands (FAPI)NCT05140746 · Stomach / esophagus | No phase | Recruiting | Ruijin Hospital | 1 |
| [68Ga]Ga-DOTA-TATE/TOC/NOCNCT07366710 · Other | No phase | Active, not recruiting | Copenhagen University Hospital, Rigshospitalet | 1 |
| [68Ga]Ga-OncoACP3NCT07559201 · Prostate – other | No phase | Recruiting | Guilin Medical University, China | 1 |
| CD38 tracersNCT07782944 · Lymphoma | No phase | Recruiting | Guilin Medical University, China | 1 |
| DLL3 tracersNCT07458906 · NETs and neuroendocrine carcinomas (other) | No phase | Recruiting | The First Affiliated Hospital of Xiamen University | 1 |
| HER2 tracersNCT01093612 · Breast | No phase | Active, not recruiting | City of Hope Medical Center | 1 |
| CEA tracersNCT02293954 · Breast | No phase | Active, not recruiting | City of Hope Medical Center | 1 |
| HER2 tracersNCT02226276 · Breast | No phase | Active, not recruiting | City of Hope Medical Center | 1 |
| Other PSMA ligandNCT05647564 · Prostate – mCRPC | No phase | Recruiting | University of Wisconsin, Madison | 1 |
| DLL3 tracersNCT07677787 · Small-cell lung cancer | No phase | Recruiting | The First Affiliated Hospital of Xiamen University | 1 |
| 2026-09 | GAME · mixedIn suspected giant cell arteritis (103 patients), ultrasound remains the best first-line test (sensitivity 82%). FDG PET is 100% specific with few inconclusive results: a second-line test, before temporal artery biopsy. | Acta Ophthalmol ↗ |
| 2026-08 | TNPET01 · promisingIn triple-negative breast cancer (22 patients), FDG and FLT are reproducible; FDG was chosen. Its drop in uptake after a single cycle predicts the final pathological response better than MRI. Small cohort; validation needed. | Clin Cancer Res ↗ |
| 2026-08 | BrIMA · positiveIn 6 European centres (148 patients), PET/CT of the surgical specimen after a low FDG dose allows margins to be corrected during surgery: 95% success vs 83% without intraoperative assessment and 87% with the usual techniques. | JAMA Surg ↗ |
| 2026-06 | IMPACT-MBC · positiveIn 200 patients with metastatic breast cancer, an FDG PET without progression after 2 weeks of treatment has a 95% NPV for progression on CT at 8 weeks. Median progression-free survival of 19.4 vs 4.1 months according to the early PET. | JAMA Oncol ↗ |
60,955 publications in PubMed for the query below; the most recent:
FDG[tiab] OR fluorodeoxyglucose[tiab] OR fludeoxyglucose[tiab]
Sources: PubChem and PubMed (NCBI), ClinicalTrials.gov and CTIS registries, approvals recorded by the atlas. PubChem data as of 28 October 2026.
Fludeoxyglucose. Theranostic Atlas, LaRadiopharmacie.fr. Data as of 27 October 2026. https://theranosticatlas.com/molecule/fdg/ (accessed [date]).
A monitoring tool with no regulatory value: check every item at its source.